Sanofi - American Depositary Shares (NQ:SNY)

39.92 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

42 43 Next >

First Wave BioPharma To Acquire ImmunogenX To Bolster Gastrointestinal-Focused Pipeline ↗

December 18, 2023

First Wave BioPharma Inc (NASDAQ: FWBI) has signed a non-binding term sheet to acquire ImmunogenX in an all-stock transaction with the combined company focused on advancing a pipeline for...

Via Benzinga

7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar ↗

December 17, 2023

While the broader healthcare sector offers myriad opportunities, these undervalued biotech picks could offer robust upside.

Via InvestorPlace

It's Almost 2024: 3 Top Stocks to Buy Before the New Year ↗

December 17, 2023

You can pick these players up for a great price right now.

Via The Motley Fool

French Drugmaker Sanofi Secures European Medicines Agency's Positive Opinion For Sleeping Sickness Treatment ↗

December 15, 2023

Sanofi SA (NASDAQ: SNY), DNDi, and the HAT-r-ACC consortium

Via Benzinga

3 Stocks to Buy Before 2024 That Can Set You Up For Life ↗

December 14, 2023

These stocks are still relatively cheap, but don't expect them to stay that way for long.

Via The Motley Fool

Why NASDAQ:SNY provides a good dividend, while having solid fundamentals. ↗

December 12, 2023

Why SANOFI-ADR (NASDAQ:SNY) provides a good dividend, while having solid fundamentals.

Via Chartmill

How Is The Market Feeling About Sanofi? ↗

November 30, 2023

Via Benzinga

Is NASDAQ:SNY a Good Fit for Dividend Investing? ↗

November 21, 2023

Is SANOFI-ADR (NASDAQ:SNY) a Good Fit for Dividend Investing?

Via Chartmill

French Pharma Giant Sanofi Drops Rare Disease Drug Pact As Federal Trade Commission Puts Antitrust Obstacle ↗

December 12, 2023

Sanofi SA (NASDAQ: SNY) said it is terminating the licensing agreement for Maze Therapeutics Inc.'s treatment for a rare genetic disorder after the Federal Trade Commission (FTC)

Via Benzinga

Vanda Pharmaceuticals Acquires Rights To Multiple Sclerosis Drug From Johnson & Johnson's Company ↗

December 07, 2023

Vanda Pharmaceuticals Inc (NASDAQ: VNDA) has acquired U.S.

Via Benzinga

Sanofi Lays Out Ambitious Plans To Bolster Its Pipeline, Highlights 12 Blockbuster Opportunities ↗

December 07, 2023

Sanofi SA (NASDAQ: SNY) says it has 12 drugs in development with a blockbus

Via Benzinga

IGM Biosciences Increases Focus On Autoimmune Diseases, Stops All Blood Cancer-Related Studies ↗

December 06, 2023

IGM Biosciences Inc (NASDAQ: IGMS) said it will focus on two strategic areas: treating colorectal cancer using IgM death receptor 5 (DR5) agonist antibodies and treating autoimmune diseases using IgM...

Via Benzinga

Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis ↗

December 06, 2023

Merck KGaA (OTC: MKGAF) (OTC:

Via Benzinga

Looking Into Sanofi's Recent Short Interest ↗

November 13, 2023

Via Benzinga

Don't overlook NASDAQ:SNY—it's a hidden gem with strong fundamentals and an attractive price tag. ↗

December 06, 2023

SANOFI-ADR (NASDAQ:SNY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

Via Chartmill

Investor Demand for Clarity Grows Amid Sanofi's Strategic R&D Shift ↗

December 05, 2023

Sanofi SA's (NASDAQ: SNY) CEO, Paul Hudson, is confronting mounting investor pressure as shareholders seek concrete details about the company's expanded R&D budget.

Via Benzinga

Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers ↗

December 01, 2023

European Medicines Agency (EMA) will request further clarifications from drugmakers of GLP-1 receptor agonists for diabetes and weight loss, including Novo Nordisk A/S's (NYSE: NVO) popular therapies...

Via Benzinga

Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment

November 30, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

2 Biotech Stocks You Can Buy and Hold for the Next Decade ↗

November 30, 2023

These stocks aren't popular on the market right now, but investors shouldn't let that scare them off.

Via The Motley Fool

Teva Pharma is the way to play the re-rise of generic drugs

November 28, 2023

Generic and specialty pharmaceutical company, Teva Pharmaceutical's stock, has underperformed for years, but a potential spinoff may be a catalyst for growth

Via MarketBeat

Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales ↗

November 27, 2023

Regeneron and Sanofi are partnered on Dupixent, a treatment for conditions tied to type 2 inflammation.

Via Investor's Business Daily

Sanofi/Regeneron's Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung Disorder ↗

November 27, 2023

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) announced the second Dupixent (dupilumab) Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) showed that...

Via Benzinga

Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease

November 27, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst ↗

November 22, 2023

Wedbush initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), noting its lead program DNTH103 as a well-positioned monoclonal antibody directed against the active form of the

Via Benzinga

US CDC Rolls Out Additional Doses For Sanofi/AstraZeneca Recently Approved Respiratory Infection Drug As Demand Surges ↗

November 17, 2023

The U.S.

Via Benzinga

Major Buyout Firms Eye Sanofi's Consumer Health Division Spinoff Valued Over $20B ↗

November 16, 2023

Sanofi SA (NYSE: SNY) has reportedly initiated talks with Rothschild & Co. to explore the possibility of spinning off its consumer health division, which could potentially value the business at over...

Via Benzinga

Don't overlook NASDAQ:SNY—it's a hidden gem with strong fundamentals and an attractive price tag. ↗

November 15, 2023

SANOFI-ADR (NASDAQ:SNY) is an undervalued gem with solid fundamentals.

Via Chartmill

MarketBeat Week in Review – 11/6 - 11/10

November 11, 2023

Stocks closed the week with a strong rally, but the rally may reverse when investors get the latest information about inflation and retail stocks next week

Via MarketBeat

Topics Artificial Intelligence Economy

Pfizer and Sanofi shares fall, which one to scoop up?

November 07, 2023

Pharmaceutical stocks aren't having a banner year; notably, two large pharmaceutical companies recently plunged to 52-week lows

Via MarketBeat

Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi ↗

November 06, 2023

The company is looking to take on Regeneron and Sanofi's Dupixent in skin diseases.

Via Investor's Business Daily

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

42 43 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.